Duchenne Muscular Dystrophy

Is Sarepta Therapeutics Worthy of Redemption?
Is Sarepta Therapeutics Worthy of Redemption?
Motley Fool
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Flag link:
Entrada raises $116M to take DMD therapy into the clinic
Entrada raises $116M to take DMD therapy into the clinic
Fierce Biotech
Entrada Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?
Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?
Endpoints
Solid Biosciences
gene therapy
Duchenne Muscular Dystrophy
Flag link:
FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy
FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy
BioSpace
Sarepta Therapeutics
Amondys 45
Duchenne Muscular Dystrophy
FDA
Flag link:
PTC aims again for FDA review of Duchenne drug despite latest miss
PTC aims again for FDA review of Duchenne drug despite latest miss
BioPharma Dive
PTC Therapeutics
Translarna
Duchenne Muscular Dystrophy
FDA
Flag link:
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
SRP-9001
Flag link:
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
BioPharma Dive
Pfizer
Sarepta Therapeutics
clinical trials
Duchenne Muscular Dystrophy
gene therapy
Flag link:
Sarepta shares first results on next-generation Duchenne drug
Sarepta shares first results on next-generation Duchenne drug
BioPharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Exondys 51
Flag link:
Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?
Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?
BioSpace
Eli Lilly
Precision Biosciences
Duchenne Muscular Dystrophy
Flag link:
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Flag link:
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Fierce Biotech
Santhera Pharmaceuticals
clinical trials
Duchenne Muscular Dystrophy
idebenone
Flag link:
FDA Grants Fast Track Designation to Pfizer's DMD Gene Therapy
FDA Grants Fast Track Designation to Pfizer's DMD Gene Therapy
BioSpace
Pfizer
fast track
FDA
Duchenne Muscular Dystrophy
PF-06939926
Flag link:
FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial
FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial
BioSpace
Solid Biosciences
FDA
clinical trials
gene therapy
Duchenne Muscular Dystrophy
Flag link:
New data bolsters Sarepta gene therapies for two deadly muscle diseases
New data bolsters Sarepta gene therapies for two deadly muscle diseases
Biopharma Dive
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
SRP-9001
SRP-9003
Flag link:
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Endpoints
Sarepta Therapeutics
gene therapy
Regenxbio
Duchenne Muscular Dystrophy
Flag link:
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Fierce Biotech
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Flag link:
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Marketwatch
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Flag link:
Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug
Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug
Investors Business Daily
Sarepta Therapeutics
FDA
fast track
Duchenne Muscular Dystrophy
casimersen
Flag link:
FDA gives speedy approval to another Duchenne drug
FDA gives speedy approval to another Duchenne drug
BioPharma Dive
FDA
NS Pharma
Japan
Duchenne Muscular Dystrophy
Viltepso
viltolarsen
Flag link:

Pages